Last reviewed · How we verify
betablocker titration
betablocker titration is a Beta-adrenergic antagonist Small molecule drug developed by Policlinico Casilino ASL RMB. It is currently FDA-approved for Hypertension, Angina pectoris, Arrhythmias (including atrial fibrillation).
Beta-blockers inhibit the effects of catecholamines on beta-adrenergic receptors, reducing heart rate, contractility, and blood pressure.
Beta blockers are used to treat conditions such as diabetes mellitus, heart failure, coronary artery disease, atrial fibrillation, and heart rate control in ICD patients with heart failure. They are small molecule medications that work by modulating the activity of nicotinic acid.
At a glance
| Generic name | betablocker titration |
|---|---|
| Sponsor | Policlinico Casilino ASL RMB |
| Drug class | Beta-adrenergic antagonist |
| Target | Beta-1 and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Beta-blockers competitively antagonize epinephrine and norepinephrine at beta-1 and beta-2 adrenergic receptors. This reduces sympathetic nervous system activity, leading to decreased cardiac output, heart rate, and myocardial oxygen demand. They are used to manage hypertension, angina, arrhythmias, and heart failure by titrating the dose to achieve target hemodynamic parameters.
Approved indications
- Hypertension
- Angina pectoris
- Arrhythmias (including atrial fibrillation)
- Heart failure
- Post-myocardial infarction management
Common side effects
- Fatigue
- Bradycardia
- Hypotension
- Dizziness
- Dyspnea
- Erectile dysfunction
- Bronchospasm (in susceptible patients)
Key clinical trials
- Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction (PHASE4)
- Rate Control Self-adjustment in Patients With Permanent or Persistent Atrial Fibrillation Using Device Home Monitoring (NA)
- Effect of Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Right Ventricular Pacing (PHASE4)
- Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- betablocker titration CI brief — competitive landscape report
- betablocker titration updates RSS · CI watch RSS
- Policlinico Casilino ASL RMB portfolio CI
Frequently asked questions about betablocker titration
What is betablocker titration?
How does betablocker titration work?
What is betablocker titration used for?
Who makes betablocker titration?
What drug class is betablocker titration in?
What development phase is betablocker titration in?
What are the side effects of betablocker titration?
What does betablocker titration target?
Related
- Drug class: All Beta-adrenergic antagonist drugs
- Target: All drugs targeting Beta-1 and beta-2 adrenergic receptors
- Manufacturer: Policlinico Casilino ASL RMB — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Angina pectoris
- Indication: Drugs for Arrhythmias (including atrial fibrillation)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing